<DOC>
	<DOCNO>NCT02084251</DOCNO>
	<brief_summary>GLP-1 analogue widely use unique advantage ( risk hypoglycemia ) due glucose dependent mechanism . Due short half-life peptide plasma , peptide administer frequently ( i.e . BID Byetta , Exenatide API ) .To improve patient compliance reduce potential adverse event associate GLP-1 analogue , long act GLP-1 analogue ( PB-119 ) , may administer weekly , develop PegBio Inc . In order provide rational dosage range study Phase Ib , safety profile , tolerance , pharmacokinetic behavior PB-119 healthy subject study randomize , control dose escalate trial .</brief_summary>
	<brief_title>Clinical Trial PB-119 Healthy Subjects ( Phase I )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female volunteer , age : 1845 ; Body weight： female &gt; = 45kg , male &gt; =50kg , BMI &gt; =1924kg/m2 Physical examination , blood routine , urine routine , liver kidney function related laboratory test normal slightly abnormal clinically significant ; Read , agree , sign informed consent ; Be able communicate investigator finish study accord protocol . Exclusion Criteria （anyone follow ) : Allergic API excipients use ( citric acid , mannitol , MetaCresol ) ; Experiencing clinically significant disease surgery within 4 week study ; Clinically significant disease history system include cardiovascular system , endocrine system , neutral system , immunology system , psychiatry，metabolic disorder ; Disease history gastrointestinal tract , liver , kidney ( example , Partial resection surgery GI tract , liver , kidney ) ; Fever history within 3 day screen ; Clinical significant abnormality find laboratory test ( blood , urine routine test ) within 2 week study ; ECG vital sign clinically significant abnormality judge Investigator ( systolic blood pressure &lt; 90mmHg ≥140mmHg ; diastolic blood pressure &lt; 60mmHg ≥90mmHg ; heart rate &lt; 50bpm &gt; 100bpm ) ; Antibody test HIV , BsAg , C hepatitis , Microspironema pallidum positive ; Alcoholics drink frequently within 6 month trial ( 14 unit alcohol , 1 unit 360mL beer , 45 ml wine 40 % alcohol content , 150mL port wine ; Addicted cigarette , tea , coffee drug ; Have specific requirement diet ( allergic food ) ; Have administer past 2 week drug ( antibiotic , anticoagulant , diuretic ) might interfere PK profile drug/drug candidate use study ; Participated clinical trial past 3 month ; Donated blood 360 ml past 3 month ; Plan pregnant spouse next 6 month ; Females administer oral contraceptive 30 day study study ; Females dose long act estrogen progestin ( injection implant ) 6 month study study ; Females childbearing age unprotected intercourse 14 day study study ; Female pregnant nursing ; Anybody might able complete study , consider appropriate investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>safety ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>Long act GLP-1 analogue</keyword>
</DOC>